These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11010607)

  • 1. Economic evaluation of enoxaparin sodium versus heparin in unstable angina. A French sub-study of the ESSENCE trial.
    Detournay B; Huet X; Fagnani F; Montalescot G
    Pharmacoeconomics; 2000 Jul; 18(1):83-9. PubMed ID: 11010607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in the secondary prevention of acute coronary syndrome.
    Brosa M; Rubio-Terrés C; Farr I; Nadipelli V; Froufe J
    Pharmacoeconomics; 2002; 20(14):979-87. PubMed ID: 12403638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes. A Canadian hospital perspective.
    Balen RM; Marra CA; Zed PJ; Cohen M; Frighetto L
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):533-42. PubMed ID: 10662478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in patients with acute coronary syndrome in Poland: modelling study from the hospital perspective.
    Orlewska E; Budaj A; Tereszkowski-Kaminski D
    Pharmacoeconomics; 2003; 21(10):737-48. PubMed ID: 12828495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?
    O'Brien BJ; Willan A; Blackhouse G; Goeree R; Cohen M; Goodman S
    Am Heart J; 2000 Mar; 139(3):423-9. PubMed ID: 10689256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease.
    Nicholson T; McGuire A; Milne R
    BMC Cardiovasc Disord; 2001; 1():2. PubMed ID: 11701090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction].
    Mark DB; Cowper PA; Berkowitz SD; Davidson-Ray L; DeLong ER; Turpie AG; Califf RM; Weatherley B; Cohen M
    Circulation; 1998 May; 97(17):1702-7. PubMed ID: 9591764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention.
    Fox KA; Antman EM; Cohen M; Bigonzi F;
    Am J Cardiol; 2002 Sep; 90(5):477-82. PubMed ID: 12208405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enoxaparin. A review of its clinical potential in the management of coronary artery disease.
    Noble S; Spencer CM
    Drugs; 1998 Aug; 56(2):259-72. PubMed ID: 9711450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events.
    Goodman SG; Cohen M; Bigonzi F; Gurfinkel EP; Radley DR; Le Iouer V; Fromell GJ; Demers C; Turpie AG; Califf RM; Fox KA; Langer A
    J Am Coll Cardiol; 2000 Sep; 36(3):693-8. PubMed ID: 10987586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial.
    Montalescot G; Philippe F; Ankri A; Vicaut E; Bearez E; Poulard JE; Carrie D; Flammang D; Dutoit A; Carayon A; Jardel C; Chevrot M; Bastard JP; Bigonzi F; Thomas D
    Circulation; 1998 Jul; 98(4):294-9. PubMed ID: 9711933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany.
    Schädlich PK; Schmidt-Lucke C; Huppertz E; Lehmacher W; Nixdorff U; Stellbrink C; Brecht JG
    Am J Cardiovasc Drugs; 2007; 7(3):199-217. PubMed ID: 17610347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness and Costs of Enoxaparin Monotherapy Versus Unfractionated Heparin Monotherapy in Treating Acute Coronary Syndrome.
    Rosenthal N; Xiao Z; Kartashov A; Levorsen A; Shah BR
    Am J Cardiovasc Drugs; 2021 Jan; 21(1):93-101. PubMed ID: 32578166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial.
    Pineo G; Lin J; Stern L; Subrahmanian T; Annemans L
    J Hosp Med; 2012 Mar; 7(3):176-82. PubMed ID: 22058011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When innovative therapies make economic sense: economic analysis of enoxaparin versus unfractionated heparin in the ESSENCE trial--an overview. Efficacy and Safety of Subcutaneous in non-Q Wave Coronary Events.
    Mark D
    Can J Cardiol; 1998 Aug; 14 Suppl E():24E-27E. PubMed ID: 9779030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
    Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
    N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An economic evaluation of the costs and benefits of heparin rationalisation in a hospital pharmacy.
    Reeves P; Cooke J; Lloyd A; Hutchings A
    Pharm World Sci; 2004 Jun; 26(3):160-8. PubMed ID: 15230364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin.
    Santopinto J; Gurfinkel EP; Torres V; Marcos E; Bozovich GE; Mautner B; McCabe CH; Antman EM
    Am Heart J; 2001 Apr; 141(4):566-72. PubMed ID: 11275921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimising outcomes: socioeconomic perspective.
    Mark DB
    Heart; 1999 Sep; 82 Suppl 1(Suppl 1):I18-20. PubMed ID: 10469674
    [No Abstract]   [Full Text] [Related]  

  • 20. A randomized trial to compare the efficacy, safety, cost and platelet aggregation effects of enoxaparin and unfractionated heparin (the ESCAPEU trial).
    Malhotra S; Bhargava VK; Grover A; Pandhi P; Sharma YP
    Int J Clin Pharmacol Ther; 2001 Mar; 39(3):110-5. PubMed ID: 11396750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.